About this episode
Join Prof Iain McInnes as he reviews two interesting papers.
Our first paper today by Charles-Schoeman and colleagues compared paraoxonase activity in RA patients treated with tofacitinib, with a focus of PON1 genotypes. Furthermore, the relationship between PON1 genotypes and the risk of MACE and malignancy were also investigated.
In our second paper, Peter Taylor and colleagues evaluated the results of several baricitinib RCTs and real-world evidence studies.
Get every episode summarized
Each time The IMID Forum publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from The IMID Forum
Discussing PsA: Bimekizumab in PsA: Clinical efficacy and updated safety profile
The IMID Forum
Apr 14, 202616:32failed
Author Interview: Professor Helena Marzo-Ortega, March 2026
The IMID Forum
Apr 9, 202637:39failed
Discussing RA: Malignancy risk in patients with RA and the evolution of JAKi pre...
The IMID Forum
Mar 26, 202610:02failed
Discussing axSpA: Symptom duration impact on bimekizumab efficacy and therapeuti...
The IMID Forum
Mar 19, 202633:29failed